Mary Reumuth
Directeur Financier/CFO chez KALA BIO, INC.
Fortune : 488 571 $ au 31/05/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Eric Trachtenberg | M | 51 |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 8 ans |
| Howard Rosen | M | 66 | 10 ans | |
| Jon Aron Olof Heimer | M | 57 | 4 ans | |
| Mark Iwicki | M | 57 | 9 ans | |
| Andrew Koven | M | 66 | 7 ans | |
| Solange Bullukian | F | 59 | 3 ans | |
| Carl Raimond | M | 53 | 4 ans | |
| Fredrik Netzel | M | 55 | 5 ans | |
| Johan Lund | M | 67 | 4 ans | |
| Marjan Farid | M | 50 | 2 ans | |
| Rickard El Tarzi | M | - | 5 ans | |
| Gregory Perry | M | 63 | 6 ans | |
| Todd Bazemore | M | 53 | 7 ans | |
| Tommi Markus Unkuri | M | 44 | 5 ans | |
| Robert Schueren | M | 62 | 2 ans | |
| Mark Blumenkranz | M | 73 | 3 ans | |
| Charles Myers | M | 70 | 3 ans | |
| Jon Hindar | M | 68 | 3 ans | |
| Nicolas Roelofs | M | 66 | 6 ans | |
| Darius Kharabi | M | 45 | 3 ans | |
| Anna Maria Marsell | F | 46 | 2 ans | |
| Hannah Deresiewicz | F | - | - | |
| Gregory Moore | M | 59 | 1 ans | |
| Oskar Hjelm | M | 39 | 4 ans | |
| Ida Grundberg | M | 41 | 5 ans | |
| Romulus Brazzell | M | 71 | 11 ans | |
| Linda Ramirez-Eaves | F | 52 | 5 ans | |
| Bruno Rossi | M | - | 1 ans | |
| Johan Holmner | M | - | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| James Levine | M | 53 | - | |
| Janet Skogan Roemer | F | 68 | 6 ans | |
| Robert A. Heft | M | 69 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 7 ans |
| Alexander Fitzpatrick | M | 57 | 4 ans | |
| Paulina Hill | M | 42 | 1 ans | |
| Charles McDermott | M | 52 | 4 ans | |
| Tina Nova | M | 70 | 1 ans | |
| Raj Shah | M | 46 | 6 ans | |
| Robert Paull | M | 47 | - | |
| Gregory Grunberg | M | 51 | 7 ans | |
| Gerald M. Haines | M | 61 | 2 ans | |
| Robert Langer | M | 74 | 9 ans | |
| Gustavo Salem | M | 60 | 3 ans | |
| Robert Tepper | M | 68 | 9 ans | |
| John F. Dee | M | 66 | 5 ans | |
| Steven Zhang | M | - | - | |
| Chen-Ming Yu | M | 50 | 1 ans | |
| Vincent Kosewski | M | - | - | |
| Barbara Littlefield | F | 66 | 4 ans | |
| James Patnoe | M | - | - | |
| Susan L. Coultas | M | - | 6 ans | |
| John Miller | M | - |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 ans |
| Kathleen McCann Kline | F | - | - | |
| Michele LaRussa | F | 54 | - | |
| Niranjan Kameswaran | M | - | - | |
| John R. Malloy | M | 65 | 2 ans | |
| Stephen P. Toon | M | - | 2 ans | |
| Gregory Powers | M | - | 2 ans | |
| Julie Smith | F | 53 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 4 ans |
| Geoffrey Peter Hazlewood | M | 73 | 7 ans | |
| Thomas Schuetz | M | 63 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 5 ans |
| Kevin Bitterman | M | 47 | - | |
| Kevin R. Bracken | M | 75 | - | |
| Fredric D. Price | M | 78 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 6 ans |
| John A. McCarthy | M | 65 | 1 ans | |
| Melvin I. Simon | M | 85 | 14 ans | |
| Mark Leschly | M | 55 | 10 ans | |
| William Baum | M | 79 | 13 ans | |
| Simon B. Rich | M | 80 | 3 ans | |
| Josiah Craver | M | - | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 45 | 65,22% |
| Suède | 19 | 27,54% |
| Canada | 6 | 8,70% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Mary Reumuth
- Réseau Personnel
